Fund managers bought shares of pharma and healthcare companies in March as they believe the domestic pharma market is expected to grow by 12-14% led by new product launches, exports, and strong growth in the chronic segment.
They were buyers in Aurobindo Pharma, Ajanta Pharma, Wockhardt, Glenmark Pharma and diagnostic companies like Dr Lal PathLabs and Vijaya Diagnostics.
They also purchased insurance stocks like SBI Life, HDFC Life, and ICICI Prudential Life Insurance after favourable guidelines on the surrender value of policies were announced by the insurance regulator IRDAI. Also, the recent removal of the age limit on availing of health insurance is seen as boosting the prospects of life insurance companies.
They were buyers in Aurobindo Pharma, Ajanta Pharma, Wockhardt, Glenmark Pharma and diagnostic companies like Dr Lal PathLabs and Vijaya Diagnostics.
They also purchased insurance stocks like SBI Life, HDFC Life, and ICICI Prudential Life Insurance after favourable guidelines on the surrender value of policies were announced by the insurance regulator IRDAI. Also, the recent removal of the age limit on availing of health insurance is seen as boosting the prospects of life insurance companies.
You may also like
'Shark Tank India' judge Vineeta Singh slams trolls who spread fake news of her death, takes legal action
Breastmilk wonder ingredient found to fight off common colds - now everyone can take it
FA Cup semi-final rules explained for Man City vs Chelsea and Man United vs Coventry City ties
China 'learning from Iran and Israel' as Xi Jinping 'plans Taiwan invasion'
